Zhejiang Huakang Pharmaceutical Co Ltd (605077) — Capital Reinvestment Ratio
Zhejiang Huakang Pharmaceutical Co Ltd (605077) has a Capital Reinvestment Ratio of 9.76x as of December 2024, meaning it reinvests 10% of its operating cash flow (CN¥146.50 Million) in capital expenditures (CN¥1.43 Billion). See 605077 net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Huakang Pharmaceutical Co Ltd Capital Reinvestment Ratio (2016–2024)
This chart tracks Zhejiang Huakang Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 9 annual periods. Check cash flow reinvestment rate of Zhejiang Huakang Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Zhejiang Huakang Pharmaceutical Co Ltd (2016–2024)
Year-by-year Capital Reinvestment Ratio for Zhejiang Huakang Pharmaceutical Co Ltd from 2016 to 2024. For live market cap and broader valuation context, see Zhejiang Huakang Pharmaceutical Co Ltd market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 9.76x | CN¥146.50 Million | CN¥1.43 Billion | ▲ +775.3% |
| 2023 | 1.11x | CN¥619.47 Million | CN¥690.70 Million | ▼ -43.8% |
| 2022 | 1.98x | CN¥271.98 Million | CN¥539.75 Million | ▲ +45.3% |
| 2021 | 1.37x | CN¥264.32 Million | CN¥360.93 Million | ▲ +81.0% |
| 2020 | 0.75x | CN¥335.24 Million | CN¥252.95 Million | ▲ +60.5% |
| 2019 | 0.47x | CN¥281.31 Million | CN¥132.21 Million | ▼ -45.4% |
| 2018 | 0.86x | CN¥140.97 Million | CN¥121.38 Million | ▲ +320.6% |
| 2017 | 0.20x | CN¥80.56 Million | CN¥16.49 Million | ▼ -24.8% |
| 2016 | 0.27x | CN¥93.02 Million | CN¥25.32 Million | — |